NCT05054218View on ClinicalTrials.gov

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

CompletedOBSERVATIONAL
Enrollment

336

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

July 16, 2022

Study Completion Date

August 29, 2022

Conditions
Covid19SARS-CoV2 Infection
Interventions
BIOLOGICAL

mRNA-1273

Participants will receive a 0.5 mL injection of the vaccine that contains a 100-μg dose of mRNA1273. The vaccine will be administered into the deltoid muscle.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

ModernaTX, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT05054218 - COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients | Biotech Hunter | Biotech Hunter